Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

2008 ◽  
Vol 116 (2) ◽  
pp. 317-328 ◽  
Author(s):  
Giuseppe Viale ◽  
Nicole Rotmensz ◽  
Patrick Maisonneuve ◽  
Luca Bottiglieri ◽  
Emilia Montagna ◽  
...  
Oncology ◽  
2005 ◽  
Vol 68 (4-6) ◽  
pp. 398-404 ◽  
Author(s):  
Shinichi Tsutsui ◽  
Hiroshi Inoue ◽  
Kazuhiro Yasuda ◽  
Kosuke Suzuki ◽  
Hidefumi Higashi ◽  
...  

2020 ◽  
pp. BMT53
Author(s):  
Guilherme Moreno Rodrigues de Souza ◽  
Anderson Fernandes Carvalho ◽  
Simone Ferreira Santiago ◽  
Maria Aparecida M R Pinho ◽  
Débora Ribeiro Ramadan ◽  
...  

It is estimated that there were 198,840 new cases of breast cancer (BC) in Brazil between 2020 and 2022. Young women who are affected by invasive BC with a triple-negative phenotype generally present more aggressive tumors that are intrinsically resistant to targeted therapies. This study evaluated the phenotypic and histological profile of BC in women up to the age of 40 years. Between 2015 and 2017, we identified 255 women with positive biopsy for carcinoma and with immunohistochemical panel, 51.76% who had a profile for luminal B (n = 132); 22.74% for triple-negative (n = 58). Of the samples, 65.88% presented histology as invasive ductal carcinoma – nonspecial type (n = 168). The results are in accordance with the literature regarding the high prevalence of triple-negative BC in young women and histological type invasive ductal carcinoma – nonspecial type.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11621-e11621
Author(s):  
Y. Izarzugaza ◽  
P. Khosravi-Shahi ◽  
A. Soria Lovelle ◽  
G. Pérez Manga

e11621 Background: Breast cancer(BC)is the most frequent neoplasm in women. Triple negative phenotype(TNP)is characterized by lack of expression of estrogen receptor(ER),progesterone receptor(PgR) and Her-2, and it is associated with a worse prognosis. Patients and Method: We conducted a retrospective study of consecutive cases of BC with TNP by immunohistochemistry(IHC),treated in our center within the last 5 years,with primary endpoint of analyzing the disease-free-survival (DFS).Second endpoints of the study were overall survival (OS),place of the first recurrence and cause of death. Results: After reviewing 295clinical histories of localized BC(with available ER,PgR and Her-2 by IHC),we found a total of 24 patients(p)with TNP(Prevalence=8.14%[95CI%: 5.3–11.9%].Ps characteristics:median age=50 years(26–74);premenopausal=55%;tumor grade:G3=40%;G2=60%;85.7% had high Ki-67(>40%);63.2% had stageIIB-III;median tumoral size=2.1cm;node positive=80%(25% with 4 or more positive nodes);96% was ductal carcinoma;56.5% was treated with mastectomy;78% with radiotherapy.Eighty-three percent of ps were treated with neoadjuvant and/or adjuvant chemotherapy with anthracyclines and taxanes:34.8% with adjuvant chemotherapy (AC60/600x4–>Paclitaxel-175x4);21.7% with neoadjuvant ATX(doxorubicin, docetaxel and capecitabine);and 26.1% with neoadjuvant AT(doxorubicin and docetaxel), and only 4 ps with adjuvant CMFx6.With a median follow-up of 36 months(m),median DSF was 42 m(95%CI: 33–51),and the probability of DSF at 3y was 67%.Median OS was 82m(95%CI: 41–123),with a probability at 5y of 52%.Thirty-eight percent(9/24)of ps had an event(3 recurrences and 6 deaths),and 100%of the deaths were caused by tumoural progression. Deaths according to the chemotherapy:75%(3/4 patients)in CMF group vs 15%(3/20)in anthracycline and taxane group(P=0.040; Fisher test).Mainly localization of the first recurrence was multiple in the 44.4%of the cases, followed by the liver(22.2%),lung(11.11%),bone(11.11%)and brain (11.11%). Conclusions: Our study confirmed the worse prognosis associated with triple negative BC.This subtype of BC must be treated with the most active cytostatic drugs in the adjuvant setting. No significant financial relationships to disclose.


2021 ◽  
pp. 106689692110085
Author(s):  
Kaitlin D. Weaver ◽  
James Isom ◽  
Ashwini Esnakula ◽  
Karen Daily ◽  
Jaya R. Asirvatham

Acinic cell carcinoma of the breast is a rare subtype of triple-negative breast cancer that recapitulates the appearance of tumors seen in salivary glands. We present the case of a 42-year-old woman with an irregular, nontender mass above the left nipple during routine obstetric appointment at 24 weeks gestation. She was subsequently diagnosed with triple-negative invasive ductal carcinoma of the left breast, Nottingham grade 3, via core needle biopsy. She was treated with neoadjuvant therapy (doxorubucin and cyclophosphamide) antenatally and paclitaxel in the postpartum period followed by left mastectomy with sentinel node biopsy. The carcinoma in the mastectomy specimen showed a spectrum of morphologic patterns with immunohistochemistry revealing strong positivity for alpha-1-antichymotrypsin, epithelial membrane antigen (EMA), lysozyme, and S100. The histomorphology paired with the immunoprofile led us to the diagnosis of acinic cell carcinoma. We retrospectively performed immunostains in the core biopsy specimen, which demonstrated GATA-3 and DOG-1 positivity. Next-generation sequencing of the postneoadjuvant specimen using a 70-gene panel revealed 2 single-nucleotide variant (SNV) mutations: tumor protein 53 (TP53) (c.747G>T) SNV mutation and rearranged during transfection (RET) (c.2899G>A) SNV mutation.


2008 ◽  
Vol 41 (4) ◽  
pp. 238-242 ◽  
Author(s):  
Naoto Kuroda ◽  
Nokiaki Fujishima ◽  
Masahiko Ohara ◽  
Takashi Hirouchi ◽  
Keiko Mizuno ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document